Hester Biosciences Limited (HESTERBIO.NS)
INR 2459.15
(1.23%)
INR 2459.15
(1.23%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.62 Billion INR | 21.35% |
| 2022 | 5.45 Billion INR | -2.91% |
| 2021 | 5.62 Billion INR | 36.76% |
| 2020 | 4.11 Billion INR | 6.91% |
| 2019 | 3.84 Billion INR | 28.39% |
| 2018 | 2.99 Billion INR | 22.7% |
| 2017 | 2.44 Billion INR | 11.88% |
| 2016 | 2.18 Billion INR | 18.37% |
| 2015 | 1.84 Billion INR | 15.37% |
| 2014 | 1.59 Billion INR | 12.31% |
| 2013 | 1.42 Billion INR | 14.97% |
| 2012 | 1.23 Billion INR | 29.63% |
| 2011 | 954.25 Million INR | 7.11% |
| 2010 | 890.87 Million INR | 10.0% |
| 2009 | 809.89 Million INR | 8.68% |
| 2008 | 745.19 Million INR | 8.56% |
| 2007 | 686.42 Million INR | 7.52% |
| 2006 | 638.38 Million INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2024 Q2 | 6.69 Billion INR | 0.0% |
| 2023 FY | 6.62 Billion INR | 21.35% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 6.83 Billion INR | 0.0% |
| 2023 Q4 | 6.62 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 5.45 Billion INR | 0.0% |
| 2022 Q2 | 6.23 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 5.45 Billion INR | -2.91% |
| 2021 Q2 | 4.3 Billion INR | 0.0% |
| 2021 Q4 | 5.62 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 5.62 Billion INR | 36.76% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 4.11 Billion INR | 6.91% |
| 2020 Q4 | 4.11 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 4.33 Billion INR | 0.0% |
| 2019 Q2 | 3.48 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 3.84 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 3.84 Billion INR | 28.39% |
| 2018 FY | 2.99 Billion INR | 22.7% |
| 2018 Q4 | 2.99 Billion INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2017 FY | 2.44 Billion INR | 11.88% |
| 2016 FY | 2.18 Billion INR | 18.37% |
| 2015 FY | 1.84 Billion INR | 15.37% |
| 2014 FY | 1.59 Billion INR | 12.31% |
| 2013 FY | 1.42 Billion INR | 14.97% |
| 2012 Q2 | 2 Billion INR | 0.0% |
| 2012 FY | 1.23 Billion INR | 29.63% |
| 2012 Q4 | 1.23 Billion INR | 0.0% |
| 2011 FY | 954.25 Million INR | 7.11% |
| 2010 FY | 890.87 Million INR | 10.0% |
| 2009 FY | 809.89 Million INR | 8.68% |
| 2008 FY | 745.19 Million INR | 8.56% |
| 2007 FY | 686.42 Million INR | 7.52% |
| 2006 FY | 638.38 Million INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Sigachi Industries Limited | 6.94 Billion INR | 4.582% |
| Ind-Swift Limited | 6.54 Billion INR | -1.203% |
| Bajaj HealthCare Limited | 7.65 Billion INR | 13.433% |
| Sakar Healthcare Limited | 3.88 Billion INR | -70.418% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 98.53% |
| Innova Captab Limited | 13.2 Billion INR | 49.856% |
| Divi's Laboratories Limited | 154.7 Billion INR | 95.719% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | 38.559% |
| Morepen Laboratories Limited | 12.93 Billion INR | 48.783% |
| Mankind Pharma Limited | 119.63 Billion INR | 94.463% |
| Sequent Scientific Limited | 15.4 Billion INR | 57.001% |
| Wanbury Limited | 3.43 Billion INR | -92.827% |
| Laurus Labs Limited | 83.87 Billion INR | 92.103% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 69.77% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 76.763% |
| Alembic Limited | 23.28 Billion INR | 71.558% |
| Hikal Limited | 24.87 Billion INR | 73.369% |
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 89.724% |
| Neuland Laboratories Limited | 18.32 Billion INR | 63.857% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 83.417% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 95.387% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 70.489% |
| Themis Medicare Limited | 5.66 Billion INR | -16.936% |
| RPG Life Sciences Limited | 5.12 Billion INR | -29.145% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 97.738% |
| Lupin Limited | 239.97 Billion INR | 97.24% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -80.54% |
| Wockhardt Limited | 76.49 Billion INR | 91.341% |
| Vaishali Pharma Limited | 799.55 Million INR | -728.392% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 74.349% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -205.119% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 94.265% |
| FDC Limited | 24.68 Billion INR | 73.164% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 98.291% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -175.907% |
| Eris Lifesciences Limited | 70.48 Billion INR | 90.603% |
| Venus Remedies Limited | 6.26 Billion INR | -5.666% |
| ZIM Laboratories Limited | 4.46 Billion INR | -48.235% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 45.435% |
| Par Drugs and Chemicals Limited | 1.01 Billion INR | -551.845% |
| Caplin Point Laboratories Limited | 26.97 Billion INR | 75.445% |
| Shilpa Medicare Limited | 30.93 Billion INR | 78.587% |
| Albert David Limited | 4.97 Billion INR | -33.004% |
| Ajanta Pharma Limited | 46.38 Billion INR | 85.72% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 70.616% |
| Solara Active Pharma Sciences Limited | 23.46 Billion INR | 71.774% |
| Gufic Biosciences Limited | 10.92 Billion INR | 39.376% |
| Windlas Biotech Limited | 6.26 Billion INR | -5.771% |
| Procter & Gamble Health Limited | 7.94 Billion INR | 16.619% |
| Aarey Drugs & Pharmaceuticals Limited | 3.04 Billion INR | -117.169% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -98.65% |
| Granules India Limited | 55.2 Billion INR | 88.003% |
| Aarti Drugs Limited | 24.32 Billion INR | 72.769% |
| Bal Pharma Limited | 3.2 Billion INR | -106.732% |
| Alkem Laboratories Limited | 155.74 Billion INR | 95.747% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 99.225% |
| Lincoln Pharmaceuticals Limited | 7 Billion INR | 5.418% |
| Medicamen Biotech Limited | 2.94 Billion INR | -124.888% |
| Unichem Laboratories Limited | 31.69 Billion INR | 79.101% |
| Bafna Pharmaceuticals Limited | 1.47 Billion INR | -348.497% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -1306.774% |
| Valiant Laboratories Limited | 3.42 Billion INR | -93.28% |
| Orchid Pharma Limited | 15.53 Billion INR | 57.374% |
| Medico Remedies Limited | 961.95 Million INR | -588.544% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 43.151% |
| Ipca Laboratories Limited | 111.01 Billion INR | 94.034% |
| Brooks Laboratories Limited | 904.45 Million INR | -632.317% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -63.678% |
| Piramal Enterprises Limited | 826.05 Billion INR | 99.198% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 95.602% |
| NATCO Pharma Limited | 69.06 Billion INR | 90.41% |
| Suven Life Sciences Limited | 2.84 Billion INR | -132.482% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -271.74% |
| Strides Pharma Science Limited | 58.39 Billion INR | 88.658% |
| Indoco Remedies Limited | 21.44 Billion INR | 69.117% |
| Alpa Laboratories Limited | 1.82 Billion INR | -262.688% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -339.022% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -28.601% |